Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Karyopharm Therapeutics (KPTI) over the last 11 years, with Q4 2024 value amounting to -$53000.0.

  • Karyopharm Therapeutics' Capital Expenditures changed N/A to -$53000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$53000.0, marking a year-over-year decrease of 12717.95%. This contributed to the annual value of $142000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q4 2024, Karyopharm Therapeutics' Capital Expenditures is -$53000.0.
  • Karyopharm Therapeutics' 5-year Capital Expenditures high stood at $207000.0 for Q4 2021, and its period low was -$53000.0 during Q4 2024.
  • In the last 4 years, Karyopharm Therapeutics' Capital Expenditures had a median value of $39000.0 in 2022 and averaged $68555.6.
  • Per our database at Business Quant, Karyopharm Therapeutics' Capital Expenditures tumbled by 7959.18% in 2020 and then skyrocketed by 68000.0% in 2022.
  • Karyopharm Therapeutics' Capital Expenditures (Quarter) stood at $119000.0 in 2020, then surged by 73.95% to $207000.0 in 2021, then plummeted by 81.16% to $39000.0 in 2022, then crashed by 235.9% to -$53000.0 in 2024.
  • Its last three reported values are -$53000.0 in Q4 2024, $195000.0 for Q1 2024, and $39000.0 during Q3 2022.